Lessons learned from mice and man: Mimicking human allergy through mouse models

Clinical Immunology

Volumn 155, Issue 1, 2014, Pages 1-16

  Graham, Michelle T ^a   Nadeau, Kari C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allergic rhinitis; Allergy; Asthma; Atopic dermatitis; Food allergy; Mouse models

Indexed keywords

IMMUNOGLOBULIN E; THYMIC STROMAL LYMPHOPOIETIN;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ALLERGY; ASTHMA; ATOPIC DERMATITIS; ATOPY; AUTOIMMUNE DISEASE; BASOPHIL; CELLULAR IMMUNITY; CHRONIC RHINOSINUSITIS; CLINICAL FEATURE; FOOD ALLERGY; GENETIC MANIPULATION; HISTOPATHOLOGY; HUMAN; HYPERSENSITIVITY; IMMUNE RESPONSE; INFLAMMATION; INSECT ALLERGY; MOUSE MODEL; MOUSE STRAIN; NONHUMAN; PASSIVE SKIN ANAPHYLAXIS; REVIEW; SPECIES COMPARISON; SYSTEMIC ANAPHYLAXIS; TH2 CELL; ANIMAL; DISEASE MODEL; IMMUNOLOGY; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; INFLAMMATION; MICE;

EID: 84907178473     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.08.002     Document Type: Review

References (177)

1. Seok J., Warren H.S., Cuenca A.G., Mindrinos M.N., Baker H.V., Xu W., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(9):3507-3512.
2. Osterburg A.R., Hexley P., Supp D.M., Robinson C.T., Noel G., Ogle C., et al. Concerns over interspecies transcriptional comparisons in mice and humans after trauma. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(36):E3370.
3. de Souza N. Model organisms: mouse models challenged. Nat. Methods 2013, 10(4):288.
4. Mestas J., Hughes C.C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 2004, 172(5):2731-2738.
5. Locksley R.M. Asthma and allergic inflammation. Cell 2010, 140(6):777-783.
6. Finkelman F.D., Wills-Karp M. Usefulness and optimization of mouse models of allergic airway disease. J. Allergy Clin. Immunol. 2008, 121(3):603-606.
7. Finkelman F.D., Hogan S.P., Hershey G.K.K., Rothenberg M.E., Wills-Karp M. Importance of cytokines in murine allergic airway disease and human asthma. J. Immunol. 2010, 184(4):1663-1674.
8. Acevedo N., Saaf A., Soderhall C., Melen E., Mandelin J., Pietras C.O., et al. Interaction between retinoid acid receptor-related orphan receptor alpha (RORA) and neuropeptide S receptor 1 (NPSR1) in asthma. PLoS One 2013, 8(4):e60111.
9. Sicherer S.H., Leung D.Y. Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2012. J. Allergy Clin. Immunol. 2012, 131(1):55-66.
10. Syed A., Kohli A., Nadeau K.C. Food allergy diagnosis and therapy: where are we now?. Immunotherapy 2013, 5(9):931-944.
11. Ingram J.L., Kraft M. IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. J. Allergy Clin. Immunol. 2012, 130(4):829-842. (quiz 843-824).
12. Gao P.S., Rafaels N.M., Mu D., Hand T., Murray T., Boguniewicz M., et al. Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum. J. Allergy Clin. Immunol. 2010, 125(6):1403-1407. (e1404).
13. Cevikbas F., Steinhoff M. IL-33: a novel danger signal system in atopic dermatitis. J. Invest. Dermatol. 2012, 132(5):1326-1329.
14. Ying S., O'Connor B., Ratoff J., Meng Q., Fang C., Cousins D., et al. Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease. J. Immunol. 2008, 181(4):2790-2798.
15. Ying S., O'Connor B., Ratoff J., Meng Q., Mallett K., Cousins D., et al. Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J. Immunol. 2005, 174(12):8183-8190.
16. Tang W., Smith S., Beaudin S., Dua B., Howie K., Gauvreau G., et al. IL-25 and IL-25 receptor expression on eosinophils from subjects with allergic asthma. Int. Arch. Allergy Immunol. 2014, 163(1):5-10.
17. Fux M., Pecaric-Petkovic T., Odermatt A., Hausmann O., Lorentz A., Bischoff S., et al. IL-33 is a mediator rather than a trigger of the acute allergic response in humans. Allergy 2014, 69(2):216-222.
18. Noti M., Wojno E.D., Kim B.S., Siracusa M.C., Giacomin P.R., Nair M.G., et al. Thymic stromal lymphopoietin-elicited basophil responses promote eosinophilic esophagitis. Nat. Med. 2013, 19(8):1005-1013.
19. Yao W., Tepper R., Kaplan M. Predisposition to the development of IL-9-secreting T cells in atopic infants. J. Allergy Clin. Immunol. 2011, 128(6):1357-1360.
20. Yao W., Zhang Y., Jabeen R., Nguyen E., Wilkes D., Tepper R., et al. Interleukin-9 is required for allergic airway inflammation mediated by the cytokine TSLP. Immunity 2013, 38(2):360-372.
21. Palmer C.N., Irvine A.D., Terron-Kwiatkowski A., Zhao Y., Liao H., Lee S.P., et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 2006, 38(4):441-446.
22. Geha R.S. Allergy and hypersensitivity. Nature versus nurture in allergy and hypersensitivity. Curr. Opin. Immunol. 2003, 15(6):603-608.
23. Sprecher E., Leung D.Y. Atopic dermatitis: scratching through the complexity of barrier dysfunction. J. Allergy Clin. Immunol. 2013, 132(5):1130-1131.
24. Brown S.J., Asai Y., Cordell H.J., Campbell L.E., Zhao Y., Liao H., et al. Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. J. Allergy Clin. Immunol. 2011, 127(3):661-667.
25. Jutel M., Akdis C.A. Immunological mechanisms of allergen-specific immunotherapy. Allergy 2011, 66(6):725-732.
26. Jin H., He R., Oyoshi M., Geha R.S. Animal models of atopic dermatitis. J. Invest. Dermatol. 2009, 129(1):31-40.
27. Boguniewicz M., Leung D.Y. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol. Rev. 2011, 242(1):233-246.
28. Smith F.J., Irvine A.D., Terron-Kwiatkowski A., Sandilands A., Campbell L.E., Zhao Y., et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat. Genet. 2006, 38(3):337-342.
29. Gittler J., Shemer A., Sua´rez-Fariñas M., Fuentes-Duculan J., Gulewicz K., Wang C., et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J. Allergy Clin. Immunol. 2012, 130(6):1344-1354.
30. Eyerich K., Novak N. Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy 2013, 68(8):974-982.
31. Fujita H. The role of IL-22 and Th22 cells in human skin diseases. J. Dermatol. Sci. 2013, 72(1):3-8.
32. Eyerich K., Pennino D., Scarponi C., Foerster S., Nasorri F., Behrendt H., et al. IL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune response. J. Allergy Clin. Immunol. 2009, 123(1):59-66.
33. Schultz Larsen F. Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample. J. Am. Acad. Dermatol. 1993, 28(5 Pt 1):719-723.
34. Dharmage S.C., Lowe A.J., Matheson M.C., Burgess J.A., Allen K.J., Abramson M.J. Atopic dermatitis and the atopic march revisited. Allergy 2013, 69(1):17-27.
35. Barnes K.C. An update on the genetics of atopic dermatitis: scratching the surface in 2009. J. Allergy Clin. Immunol. 2010, 125(1):16-29. (e11-11; quiz 30-11).
36. Pellerin L., Henry J., Hsu C.Y., Balica S., Jean-Decoster C., Mechin M.C., et al. Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. J. Allergy Clin. Immunol. 2013, 131(4):1094-1102.
37. Bieber T. Atopic dermatitis. N. Engl. J. Med. 2008, 358(14):1483-1494.
38. Barker J.N., Palmer C.N., Zhao Y., Liao H., Hull P.R., Lee S.P., et al. Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood. J. Invest. Dermatol. 2007, 127(3):564-567.
39. Asai Y., Greenwood C., Hull P.R., Alizadehfar R., Ben-Shoshan M., Brown S.J., et al. Filaggrin gene mutation associations with peanut allergy persist despite variations in peanut allergy diagnostic criteria or asthma status. J. Allergy Clin. Immunol. 2013, 132(1):239-242.
40. Margolis D.J., Gupta J., Apter A.J., Ganguly T., Hoffstad O., Papadopoulos M., et al. Filaggrin-2 variation is associated with more persistent atopic dermatitis in African American subjects. J. Allergy Clin. Immunol. 2013, 133(3):784-789.
41. Saunders S.P., Goh C.S., Brown S.J., Palmer C.N., Porter R.M., Cole C., et al. Tmem79/Matt is the matted mouse gene and is a predisposing gene for atopic dermatitis in human subjects. J. Allergy Clin. Immunol. 2013, 132(5):1121-1129.
42. Rebane A., Zimmermann M., Aab A., Baurecht H., Koreck A., Karelson M., et al. Mechanisms of IFN-γ-induced apoptosis of human skin keratinocytes in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2012, 129(5):1297-1306.
43. De Benedetto A., Rafaels N., McGirt L., Ivanov A., Georas S., Cheadle C., et al. Tight junction defects in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2011, 127(3):773.
44. Kim B.S., Siracusa M.C., Saenz S.A., Noti M., Monticelli L.A., Sonnenberg G.F., et al. TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci. Transl. Med. 2013, 5(170):170ra116.
45. Soumelis V., Reche P.A., Kanzler H., Yuan W., Edward G., Homey B., et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat. Immunol. 2002, 3(7):673-680.
46. Kinoshita H., Takai T., Le T., Kamijo S., Wang X., Ushio H., et al. Cytokine milieu modulates release of thymic stromal lymphopoietin from human keratinocytes stimulated with double-stranded RNA. J. Allergy Clin. Immunol. 2009, 123(1):179-186.
47. Savinko T., Matikainen S., Saarialho-Kere U., Lehto M., Wang G., Lehtima¨ki S., et al. IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J. Invest. Dermatol. 2012, 132(5):1392-1400.
48. Ong P., Ohtake T., Brandt C., Strickland I., Boguniewicz M., Ganz T., et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 2002, 347(15):1151-1160.
49. Alase A., Seltmann J., Werfel T., Wittmann M. Interleukin-33 modulates the expression of human β-defensin 2 in human primary keratinocytes and may influence the susceptibility to bacterial superinfection in acute atopic dermatitis. Br. J. Dermatol. 2012, 167(6):1386-1389.
50. Goswami R., Kaplan M. A brief history of IL-9. J. Immunol. 2011, 186(6):3283-3288.
51. Soyer O.U., Akdis M., Ring J., Behrendt H., Crameri R., Lauener R., et al. Mechanisms of peripheral tolerance to allergens. Allergy 2013, 68(2):161-170.
52. Licona-Limon P., Kim L.K., Palm N.W., Flavell R.A. TH2, allergy and group 2 innate lymphoid cells. Nat. Immunol. 2013, 14(6):536-542.
53. Halabi-Tawil M., Ruemmele F.M., Fraitag S., Rieux-Laucat F., Neven B., Brousse N., et al. Cutaneous manifestations of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Br. J. Dermatol. 2009, 160(3):645-651.
54. Szegedi A., Barath S., Nagy G., Szodoray P., Gal M., Sipka S., et al. Regulatory T cells in atopic dermatitis: epidermal dendritic cell clusters may contribute to their local expansion. Br. J. Dermatol. 2009, 160(5):984-993.
55. Lesiak A., Smolewski P., Sobolewska-Sztychny D., Sysa-Jedrzejowska A., Narbutt J. The role of T-regulatory cells and Toll-like receptors 2 and 4 in atopic dermatitis. Scand. J. Immunol. 2012, 76(4):405-410.
56. Verhagen J., Akdis M., Traidl-Hoffmann C., Schmid-Grendelmeier P., Hijnen D., Knol E.F., et al. Absence of T-regulatory cell expression and function in atopic dermatitis skin. J. Allergy Clin. Immunol. 2006, 117(1):176-183.
57. Volz T., Skabytska Y., Guenova E., Chen K.M., Frick J.S., Kirschning C.J., et al. Nonpathogenic bacteria alleviating atopic dermatitis inflammation induce IL-10-producing dendritic cells and regulatory Tr1 cells. J. Invest. Dermatol. 2014, 134(1):96-104.
58. Salimi M., Barlow J.L., Saunders S.P., Xue L., Gutowska-Owsiak D., Wang X., et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J. Exp. Med. 2013, 210(13):2939-2950.
59. Moniaga C.S., Egawa G., Kawasaki H., Hara-Chikuma M., Honda T., Tanizaki H., et al. Flaky tail mouse denotes human atopic dermatitis in the steady state and by topical application with Dermatophagoides pteronyssinus extract. Am. J. Pathol. 2010, 176(5):2385-2393.
60. Scharschmidt T.C., Man M.Q., Hatano Y., Crumrine D., Gunathilake R., Sundberg J.P., et al. Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thresholds to irritants and haptens. J. Allergy Clin. Immunol. 2009, 124(3):496-506. (506 e491-496).
61. Fallon P.G., Sasaki T., Sandilands A., Campbell L.E., Saunders S.P., Mangan N.E., et al. A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming. Nat. Genet. 2009, 41(5):602-608.
62. Leyva-Castillo J.M., Hener P., Jiang H., Li M. TSLP produced by keratinocytes promotes allergen sensitization through skin and thereby triggers atopic march in mice. J. Invest. Dermatol. 2013, 133(1):154-163.
63. Ziegler S.F., Roan F., Bell B.D., Stoklasek T.A., Kitajima M., Han H. The biology of thymic stromal lymphopoietin (TSLP). Adv. Pharmacol. 2013, 66:129-155.
64. Wilson S.R., The L., Batia L.M., Beattie K., Katibah G.E., McClain S.P., et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell 2013, 155(2):285-295.
65. Li M., Hener P., Zhang Z., Ganti K.P., Metzger D., Chambon P. Induction of thymic stromal lymphopoietin expression in keratinocytes is necessary for generating an atopic dermatitis upon application of the active vitamin D3 analogue MC903 on mouse skin. J. Invest. Dermatol. 2009, 129(2):498-502.
66. Li M., Hener P., Zhang Z., Kato S., Metzger D., Chambon P. Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(31):11736-11741.
67. Li M., Messaddeq N., Teletin M., Pasquali J.L., Metzger D., Chambon P. Retinoid X receptor ablation in adult mouse keratinocytes generates an atopic dermatitis triggered by thymic stromal lymphopoietin. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(41):14795-14800.
68. Searing D.A., Leung D.Y. Vitamin D in atopic dermatitis, asthma and allergic diseases. Immunol. Allergy Clin. N. Am. 2010, 30(3):397-409.
69. Hollams E.M. Vitamin D, and atopy and asthma phenotypes in children. Curr. Opin. Allergy Clin. Immunol. 2012, 12(3):228-234.
70. Jones A.P., Tulic M.K., Rueter K., Prescott S.L. Vitamin D and allergic disease: sunlight at the end of the tunnel?. Nutrients 2012, 4(1):13-28.
71. Nour B., Patricia D.-M., John D.W., Jean-Claude S., Isabella A.-M. Cord serum 25-hydroxyvitamin D and risk of early childhood transient wheezing and atopic dermatitis. J. Allergy Clin. Immunol. 2014, 133.
72. Dumortier A., Durham A.D., Di Piazza M., Vauclair S., Koch U., Ferrand G., et al. Atopic dermatitis-like disease and associated lethal myeloproliferative disorder arise from loss of Notch signaling in the murine skin. PLoS One 2010, 5(2):e9258.
73. Demehri S., Liu Z., Lee J., Lin M.H., Crosby S.D., Roberts C.J., et al. Notch-deficient skin induces a lethal systemic B-lymphoproliferative disorder by secreting TSLP, a sentinel for epidermal integrity. PLoS Biol. 2008, 6(5):e123.
74. Yockey L.J., Demehri S., Turkoz M., Turkoz A., Ahern P.P., Jassim O., et al. The absence of a microbiota enhances TSLP expression in mice with defective skin barrier but does not affect the severity of their allergic inflammation. J. Invest. Dermatol. 2013, 133(12):2714-2721.
75. Tanaka A., Matsuda H. Evaluation of itch by using NC/NgaTnd mice: a model of human atopic dermatitis. J. Biomed. Biotechnol. 2011, 2011:790436.
76. Kohara Y., Tanabe K., Matsuoka K., Kanda N., Matsuda H., Karasuyama H., et al. A major determinant quantitative-trait locus responsible for atopic dermatitis-like skin lesions in NC/Nga mice is located on chromosome 9. Immunogenetics 2001, 53(1):15-21.
77. Nakagawa R., Yoshida H., Asakawa M., Tamiya T., Inoue N., Morita R., et al. Pyridone 6, a pan-JAK inhibitor, ameliorates allergic skin inflammation of NC/Nga mice via suppression of Th2 and enhancement of Th17. J. Immunol. 2011, 187(9):4611-4620.
78. Agache I., Akdis C., Jutel M., Virchow J.C. Untangling asthma phenotypes and endotypes. Allergy 2012, 67(7):835-846.
79. Lambrecht B.N., Hammad H. Asthma: the importance of dysregulated barrier immunity. Eur. J. Immunol. 2013, 43(12):3125-3137.
80. Corrigan C. Mechanisms of asthma. Medicine 2012, 40(5):223-227.
81. Hatzivlassiou M., Grainge C., Kehagia V., Lau L., Howarth P. The allergen specificity of the late asthmatic reaction. Allergy 2010, 65(3):355-358.
82. Seroogy C., Gern J. The role of T regulatory cells in asthma. J. Allergy Clin. Immunol. 2005, 116(5):996-999.
83. Runyon R., Cachola L., Rajeshuni N., Hunter T., Garcia M., Ahn R., et al. Asthma discordance in twins is linked to epigenetic modifications of T cells. PLoS One 2012, 7(11).
84. Nadeau K., McDonald-Hyman C., Noth E., Pratt B., Hammond S., Balmes J., et al. Ambient air pollution impairs regulatory T-cell function in asthma. J. Allergy Clin. Immunol. 2010, 126(4):845.
85. Sakaguchi S., Vignali D.A., Rudensky A., Niec R., Waldmann H. The plasticity and stability of regulatory T cells. Nat. Rev. Immunol. 2013, 13(6):461-467.
86. Nguyen K., Vanichsarn C., Nadeau K. Impaired IL-10-dependent induction of tolerogenic dendritic cells by CD4+ CD25hiCD127lo/- natural regulatory T cells in human allergic asthma. Am. J. Respir. Crit. Care Med. 2009, 180(9):823-833.
87. Noh G., Lee J. Regulatory B cells and allergic diseases. Allergy Asthma Immunol. Res. 2011, 3(3):168-177.
88. Chu K.-H., Chiang B.-L. Regulatory T cells induced by mucosal B cells alleviate allergic airway hypersensitivity. Am. J. Respir. Cell Mol. Biol. 2012, 46(5):651-659.
89. Fillatreau S., Sweenie C., McGeachy M., Gray D., Anderton S. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 2002, 3(10):944-950.
90. Mauri C., Gray D., Mushtaq N., Londei M. Prevention of arthritis by interleukin 10-producing B cells. J. Exp. Med. 2003, 197(4):489-501.
91. Blair P., Noreña L., Flores-Borja F., Rawlings D., Isenberg D., Ehrenstein M., et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010, 32(1):129-140.
92. van de Veen W., Stanic B., Yaman G., Wawrzyniak M., So¨llner S., Akdis D., et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J. Allergy Clin. Immunol. 2013, 131(4):1204-1212.
93. van der Vlugt L., Mlejnek E., Ozir-Fazalalikhan A., Bonas M., Dijksman T., Labuda L., et al. CD24(hi) CD27(+) B cells from allergic asthma patients have impaired regulatory activity in response to LPS. Clin. Exp. Allergy 2013, 44(4):517-528.
94. Kleinjan A., Klein Wolterink R., Levani Y., de Bruijn M., Hoogsteden H., van Nimwegen M., et al. Enforced expression of Gata3 in T cells and group 2 innate lymphoid cells increases susceptibility to allergic airway inflammation in mice. J. Immunol. 2014, 192(4):1385-1394.
95. Lee J., Dimina D., Macias M., Ochkur S., McGarry M., O'Neill K., et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 2004, 305(5691):1773-1776.
96. Wills-Karp M., Luyimbazi J., Xu X., Schofield B., Neben T., Karp C., et al. Interleukin-13: central mediator of allergic asthma. Science 1998, 282(5397):2258-2261.
97. Doganci A., Eigenbrod T., Krug N., De Sanctis G., Hausding M., Erpenbeck V., et al. The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J. Clin. Invest. 2005, 115(2):313-325.
98. Temann U.-A., Ray P., Flavell R. Pulmonary overexpression of IL-9 induces Th2 cytokine expression, leading to immune pathology. J. Clin. Invest. 2002, 109(1):29-39.
99. Zhou B., Comeau M., De Smedt T., Liggitt H., Dahl M., Lewis D., et al. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat. Immunol. 2005, 6(10):1047-1053.
100. Han H., Headley M., Xu W., Comeau M., Zhou B., Ziegler S. Thymic stromal lymphopoietin amplifies the differentiation of alternatively activated macrophages. J. Immunol. 2013, 190(3):904-912.
101. Yadava K., Massacand J., Mosconi I., Nicod L.P., Harris N.L., Marsland B.J. Thymic stromal lymphopoietin plays divergent roles in murine models of atopic and non-atopic airway inflammation. Allergy 2014, 10.1111/all.12469.
102. Lee H., Rhee C., Kang J., Byun J., Choi J., Kim S., et al. Blockade of IL-33/ST2 ameliorates airway inflammation in a murine model of allergic asthma. Exp. Lung Res. 2014, 40(2):66-76.
103. Barlow J., Peel S., Fox J., Panova V., Hardman C., Camelo A., et al. IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction. J. Allergy Clin. Immunol. 2013, 132(4):933-941.
104. Singh A., Carson W., Secor E., Guernsey L., Flavell R., Clark R., et al. Regulatory role of B cells in a murine model of allergic airway disease. J. Immunol. 2008, 180(11):7318-7326.
105. Amu S., Saunders S., Kronenberg M., Mangan N., Atzberger A., Fallon P. Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model. J. Allergy Clin. Immunol. 2010, 125(5). (1114-730850304).
106. Natarajan P., Singh A., McNamara J., Secor E., Guernsey L., Thrall R., et al. Regulatory B cells from hilar lymph nodes of tolerant mice in a murine model of allergic airway disease are CD5+, express TGF-β, and co-localize with CD4+Foxp3+ T cells. Mucosal Immunol. 2012, 5(6):691-701.
107. Zosky G., Larcombe A., White O., Burchell J., Janosi T., Hantos Z., et al. Ovalbumin-sensitized mice are good models for airway hyperresponsiveness but not acute physiological responses to allergen inhalation. Clin. Exp. Allergy 2008, 38(5):829-838.
108. Irvin C., Bates J. Physiologic dysfunction of the asthmatic lung: what's going on down there, anyway?. Proc. Am. Thorac. Soc. 2009, 6(3):306-311.
109. Bates J., Rincon M., Irvin C. Animal models of asthma. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009, 297(3):10.
110. De Vooght V., Smulders S., Haenen S., Belmans J., Opdenakker G., Verbeken E., et al. Neutrophil and eosinophil granulocytes as key players in a mouse model of chemical-induced asthma. Toxicol. Sci. 2013, 131(2):406-418.
111. Lemiere C., Chaboillez S., Bohadana A., Blais L., Maghni K. Noneosinophilic responders with occupational asthma: a phenotype associated with a poor asthma prognosis. J. Allergy Clin. Immunol. 2013, 133(3):883-885.
112. De Vooght V., Carlier V., Devos F., Haenen S., Verbeken E., Nemery B., et al. B-lymphocytes as key players in chemical-induced asthma. PLoS One 2013, 8(12).
113. Dearman R., Moussavi A., Kemeny D., Kimber I. Contribution of CD4+ and CD8+ T lymphocyte subsets to the cytokine secretion patterns induced in mice during sensitization to contact and respiratory chemical allergens. Immunology 1996, 89(4):502-510.
114. Herrick C., Xu L., Wisnewski A., Das J., Redlich C., Bottomly K. A novel mouse model of diisocyanate-induced asthma showing allergic-type inflammation in the lung after inhaled antigen challenge. J. Allergy Clin. Immunol. 2002, 109(5):873-878.
115. Herrick C., Das J., Xu L., Wisnewski A., Redlich C., Bottomly K. Differential roles for CD4 and CD8 T cells after diisocyanate sensitization: genetic control of TH2-induced lung inflammation. J. Allergy Clin. Immunol. 2003, 111(5):1087-1094.
116. Sicherer S., Sampson H. Food allergy: epidemiology, pathogenesis, diagnosis, and treatment. J. Allergy Clin. Immunol. 2013, 133(2):291-307.
117. Panel N.I.-S.E., Boyce J., Assa'ad A., Burks A., Jones S., Sampson H., et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J. Allergy Clin. Immunol. 2010, 126(6 Suppl):58.
118. Gupta R.S., Springston E.E., Warrier M.R., Smith B., Kumar R., Pongracic J., et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics 2011, 128(1):e9-e17.
119. Gupta R. Anaphylaxis in the young adult population. Am. J. Med. 2014, 127(1 Suppl):24.
120. Burks A., Tang M., Sicherer S., Muraro A., Eigenmann P., Ebisawa M., et al. ICON: food allergy. J. Allergy Clin. Immunol. 2012, 129(4):906-920.
121. Akdis C., Blesken T., Akdis M., Alkan S., Wu¨thrich B., Heusser C., et al. Induction and differential regulation of bee venom phospholipase A2-specific human IgE and IgG4 antibodies in vitro requires allergen-specific and nonspecific activation of T and B cells. J. Allergy Clin. Immunol. 1997, 99(3):345-353.
122. Syed A., Garcia M., Lyu S.-C., Bucayu R., Kohli A., Ishida S., et al. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J. Allergy Clin. Immunol. 2014, 133(2). (500-1558327296).
123. Ozdemir C., Kucuksezer U., Akdis M., Akdis C. Mechanisms of immunotherapy to wasp and bee venom. Clin. Exp. Allergy 2011, 41(9):1226-1234.
124. Nadif R., Zerimech F., Bouzigon E., Matran R. The role of eosinophils and basophils in allergic diseases considering genetic findings. Curr. Opin. Allergy Clin. Immunol. 2013, 13(5):507-513.
125. Chu D., Llop-Guevara A., Walker T., Flader K., Goncharova S., Boudreau J., et al. IL-33, but not thymic stromal lymphopoietin or IL-25, is central to mite and peanut allergic sensitization. J. Allergy Clin. Immunol. 2013, 131(1):187.
126. Pushparaj P., Tay H., H'ng S., Pitman N., Xu D., McKenzie A., et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(24):9773-9778.
127. Komai-Koma M., Brombacher F., Pushparaj P., Arendse B., McSharry C., Alexander J., et al. Interleukin-33 amplifies IgE synthesis and triggers mast cell degranulation via interleukin-4 in nai¨ve mice. Allergy 2012, 67(9):1118-1126.
128. Gernez Y., Tirouvanziam R., Yu G., Ghosn E., Reshamwala N., Nguyen T., et al. Basophil CD203c levels are increased at baseline and can be used to monitor omalizumab treatment in subjects with nut allergy. Int. Arch. Allergy Immunol. 2011, 154(4):318-327.
129. Finkelman F. Anaphylaxis: lessons from mouse models. J. Allergy Clin. Immunol. 2007, 120(3):506.
130. Reber L., Marichal T., Mukai K., Kita Y., Tokuoka S., Roers A., et al. Selective ablation of mast cells or basophils reduces peanut-induced anaphylaxis in mice. J. Allergy Clin. Immunol. 2013, 132(4):881.
131. Mathias C.B., Hobson S.A., Garcia-Lloret M., Lawson G., Poddighe D., Freyschmidt E.J., et al. IgE-mediated systemic anaphylaxis and impaired tolerance to food antigens in mice with enhanced IL-4 receptor signaling. J. Allergy Clin. Immunol. 2011, 127(3):795-805. (e791-796).
132. Curciarello R., Smaldini P., Candreva A., Gonza´lez V., Parisi G., Cauerhff A., et al. Targeting a cross-reactive Gly m 5 soy peptide as responsible for hypersensitivity reactions in a milk allergy mouse model. PLoS One 2014, 9(1).
133. Bailo´n E., Cueto-Sola M., Utrilla P., Rodri´guez-Ruiz J., Garrido-Mesa N., Zarzuelo A., et al. A shorter and more specific oral sensitization-based experimental model of food allergy in mice. J. Immunol. Methods 2012, 381(1-2):41-49.
134. van Esch B., van Bilsen J., Jeurink P., Garssen J., Penninks A., Smit J., et al. Interlaboratory evaluation of a cow's milk allergy mouse model to assess the allergenicity of hydrolysed cow's milk based infant formulas. Toxicol. Lett. 2013, 220(1):95-102.
135. van den Elsen L., van Esch B., Hofman G., Kant J., van de Heijning B., Garssen J., et al. Dietary long chain n-3 polyunsaturated fatty acids prevent allergic sensitization to cow's milk protein in mice. Clin. Exp. Allergy 2013, 43(7):798-810.
136. Denery-Papini S., Bodinier M., Pineau F., Triballeau S., Tranquet O., Adel-Patient K., et al. Immunoglobulin-E-binding epitopes of wheat allergens in patients with food allergy to wheat and in mice experimentally sensitized to wheat proteins. Clin. Exp. Allergy 2011, 41(10):1478-1492.
137. Vinje N., Namork E., Løvik M. Anaphylactic reactions in mice with fenugreek allergy. Scand. J. Immunol. 2011, 74(4):342-353.
138. Gizzarelli F., Corinti S., Barletta B., Iacovacci P., Brunetto B., Butteroni C., et al. Evaluation of allergenicity of genetically modified soybean protein extract in a murine model of oral allergen-specific sensitization. Clin. Exp. Allergy 2006, 36(2):238-248.
139. Pons L., Ponnappan U., Hall R., Simpson P., Cockrell G., West C., et al. Soy immunotherapy for peanut-allergic mice: modulation of the peanut-allergic response. J. Allergy Clin. Immunol. 2004, 114(4):915-921.
140. Oyoshi M., Oettgen H., Chatila T., Geha R., Bryce P. Food allergy: insights into etiology, prevention, and treatment provided by murine models. J. Allergy Clin. Immunol. 2014, 133(2):309-317.
141. Padavattan S., Schirmer T., Schmidt M., Akdis C., Valenta R., Mittermann I., et al. Identification of a B-cell epitope of hyaluronidase, a major bee venom allergen, from its crystal structure in complex with a specific Fab. J. Mol. Biol. 2007, 368(3):742-752.
142. Reimers A., Weber M., Mu¨ller U. Are anaphylactic reactions to snake bites immunoglobulin E-mediated?. Clin. Exp. Allergy 2000, 30(2):276-282.
143. Madero M., Ga´mez C., Madero M., Ferna´ndez-Nieto M., Sastre J., del Pozo V. Characterization of allergens in four South American snake species. Int. Arch. Allergy Immunol. 2009, 150(3):307-310.
144. Palm N., Rosenstein R., Yu S., Schenten D., Florsheim E., Medzhitov R. Bee venom phospholipase A2 induces a primary type 2 response that is dependent on the receptor ST2 and confers protective immunity. Immunity 2013, 39(5):976-985.
145. Marichal T., Starkl P., Reber L., Kalesnikoff J., Oettgen H., Tsai M., et al. A beneficial role for immunoglobulin E in host defense against honeybee venom. Immunity 2013, 39(5):963-975.
146. Rothenberg M.E. Biology and treatment of eosinophilic esophagitis. Gastroenterology 2009, 137(4):1238-1249.
147. Sherrill J.D., Rothenberg M.E. Genetic dissection of eosinophilic esophagitis provides insight into disease pathogenesis and treatment strategies. J. Allergy Clin. Immunol. 2011, 128(1):23-32. (quiz 33-24).
148. Mishra A., Wang M., Pemmaraju V.R., Collins M.H., Fulkerson P.C., Abonia J.P., et al. Esophageal remodeling develops as a consequence of tissue specific IL-5-induced eosinophilia. Gastroenterology 2008, 134(1):204-214.
149. Mishra A., Schlotman J., Wang M., Rothenberg M.E. Critical role for adaptive T cell immunity in experimental eosinophilic esophagitis in mice. J. Leukoc. Biol. 2007, 81(4):916-924.
150. Blanchard C., Mingler M.K., Vicario M., Abonia J.P., Wu Y.Y., Lu T.X., et al. IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. J. Allergy Clin. Immunol. 2007, 120(6):1292-1300.
151. Sherrill J.D., Gao P.S., Stucke E.M., Blanchard C., Collins M.H., Putnam P.E., et al. Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis. J. Allergy Clin. Immunol. 2010, 126(1):160-165. (e163).
152. Kottyan L.C., Davis B.P., Sherrill J.D., Liu K., Rochman M., Kaufman K., et al. Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease. Nat. Genet. 2014, 46(8):895-900.
153. Blanchard C., Stucke E.M., Burwinkel K., Caldwell J.M., Collins M.H., Ahrens A., et al. Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. J. Immunol. 2010, 184(7):4033-4041.
154. Groschwitz K., Hogan S. Intestinal barrier function: molecular regulation and disease pathogenesis. J. Allergy Clin. Immunol. 2009, 124(1):3.
155. Kariyawasam H., Rotiroti G. Allergic rhinitis, chronic rhinosinusitis and asthma: unravelling a complex relationship. Curr. Opin. Otolaryngol. Head Neck Surg. 2013, 21(1):79-86.
156. Kirtsreesakul V., Naclerio R. Role of allergy in rhinosinusitis. Curr. Opin. Allergy Clin. Immunol. 2004, 4(1):17-23.
157. Tsilochristou O., Douladiris N., Makris M., Papadopoulos N. Pediatric allergic rhinitis and asthma: can the march be halted?. Paediatr. Drugs 2013, 15(6):431-440.
158. Scadding G. Cytokine profiles in allergic rhinitis. Curr. Allergy Asthma Rep. 2014, 14(5):435.
159. Doherty T., Scott D., Walford H., Khorram N., Lund S., Baum R., et al. Allergen challenge in allergic rhinitis rapidly induces increased peripheral blood type 2 innate lymphoid cells that express CD84. J. Allergy Clin. Immunol. 2014, 133(4):1203-1205.
160. Akdis C., Bachert C., Cingi C., Dykewicz M., Hellings P., Naclerio R., et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J. Allergy Clin. Immunol. 2013, 131(6):1479-1490.
161. Schleimer R., Kato A., Peters A., Conley D., Kim J., Liu M., et al. Epithelium, inflammation, and immunity in the upper airways of humans: studies in chronic rhinosinusitis. Proc. Am. Thorac. Soc. 2009, 6(3):288-294.
162. Jiang X.-D., Li G.-Y., Li L., Dong Z., Zhu D.-D. The characterization of IL-17A expression in patients with chronic rhinosinusitis with nasal polyps. Am. J. Rhinol. Allergy 2011, 25(5):5.
163. Wei P., Hu G.-H., Kang H.-Y., Yao H.-B., Kou W., Zhang C., et al. Role of the aryl hydrocarbon receptor in the pathogenesis of chronic rhinosinusitis with nasal polyps. Inflammation 2014, 37(2):387-395.
164. Zhang N., Van Zele T., Perez-Novo C., Van Bruaene N., Holtappels G., DeRuyck N., et al. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. J. Allergy Clin. Immunol. 2008, 122(5):961-968.
165. Mahdavinia M., Carter R., Ocampo C., Stevens W., Kato A., Tan B., et al. Basophils are elevated in nasal polyps of patients with chronic rhinosinusitis without aspirin sensitivity. J. Allergy Clin. Immunol. 2014, 133(6):1759-1763.
166. Kim Y., Munoz A., Hwang P., Nadeau K. Migration of regulatory T cells toward airway epithelial cells is impaired in chronic rhinosinusitis with nasal polyposis. Clin. Immunol. 2010, 137(1):111-121.
167. Soyka M., Wawrzyniak P., Eiwegger T., Holzmann D., Treis A., Wanke K., et al. Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-γ and IL-4. J. Allergy Clin. Immunol. 2012, 130(5):1087.
168. Morjaria J., Caruso M., Rosalia E., Russo C., Polosa R. Preventing progression of allergic rhinitis to asthma. Curr. Allergy Asthma Rep. 2014, 14(2):412.
169. Carr V., Robinson A. Induction of allergic rhinitis in mice. Methods Mol. Biol. 2013, 1032:145-158.
170. Kim D., Khalmuratova R., Hur D., Jeon S.-Y., Kim S.-W., Shin H.-W., et al. Staphylococcus aureus enterotoxin B contributes to induction of nasal polypoid lesions in an allergic rhinosinusitis murine model. Am. J. Rhinol. Allergy 2011, 25(6):61.
171. Wang Y.-H.H., Hogan S.P., Fulkerson P.C., Abonia J.P., Rothenberg M.E. Expanding the paradigm of eosinophilic esophagitis: mast cells and IL-9. J. Allergy Clin. Immunol. 2013, 131(6):1583-1585.
172. Wenzel S., Ford L., Pearlman D., Spector S., Sher L., Skobieranda F., et al. Dupilumab in persistent asthma with elevated eosinophil levels. N. Engl. J. Med. 2013, 368(26):2455-2466.
173. Beck L.A., Thac¸i D., Hamilton J.D., Graham N.M., Bieber T., Rocklin R., et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N. Engl. J. Med. 2014, 371(2):130-139.
174. Gauvreau G.M., O'Byrne P.M., Boulet L.-P.P., Wang Y., Cockcroft D., Bigler J., et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N. Engl. J. Med. 2014, 370(22):2102-2110.
175. Nguyen T.-H.T., Casale T. Immune modulation for treatment of allergic disease. Immunol. Rev. 2011, 242(1):258-271.
176. Marrs T., Bruce K., Logan K., Rivett D., Perkin M., Lack G., et al. Is there an association between microbial exposure and food allergy? A systematic review. Pediatr. Allergy Immunol. 2013, 24(4). (311-1935228928).
177. Penders J., Gerhold K., Thijs C., Zimmermann K., Wahn U., Lau S., et al. New insights into the hygiene hypothesis in allergic diseases: mediation of sibling and birth mode effects by the gut microbiota. Gut Microbes 2014, 5(2).